Rifampin

"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Descriptor ID	D012293
MeSH Number(s)	D03.633.400.811.700 D04.345.295.750.700
Concept/Terms	Rifampin Rifampin Benemycin Rifampicin Rimactan Rimactan Tubocin Tubocin Rifadin Rifadin Rimactane Rimactane

Below are MeSH descriptors whose meaning is more general than "Rifampin".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Rifamycins [D03.633.400.811]
Rifampin [D03.633.400.811.700]
Polycyclic Compounds [D04]
Macrocyclic Compounds [D04.345]
Lactams, Macrocyclic [D04.345.295]
Rifamycins [D04.345.295.750]
Rifampin [D04.345.295.750.700]

Below are MeSH descriptors whose meaning is related to "Rifampin".

Below are MeSH descriptors whose meaning is more specific than "Rifampin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.

Bar chart showing 8 publications over 5 distinct years, with a maximum of 2 publications in 2017 and 2023 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	1	0	1
2017	1	1	2
2022	1	0	1
2023	1	1	2
2024	1	1	2

Below are the most recent publications written about "Rifampin" by people in Profiles.

Sivakumaran P, Barros B, Antonio Dias VL, Lockwood DN, Walker SL. A retrospective cohort study of monthly rifampicin, ofloxacin and minocycline in the management of leprosy at the Hospital for Tropical Diseases, London, United Kingdom. PLoS Negl Trop Dis. 2024 Dec; 18(12):e0012699.

View in: PubMed
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.

View in: PubMed
Sharma S, Takkella D, Vishwakarma J, Gavvala K. Spectroscopy and dynamics of beta-lactoglobulin complexed with rifampicin. J Biomol Struct Dyn. 2024; 42(24):13460-13473.

View in: PubMed
Lee HJ, Kim HK, Kim BS, Han KD, Park CS, Rhee TM, Park JB, Lee H, Kim YJ. Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment. Sci Rep. 2023 02 04; 13(1):2060.

View in: PubMed
Taylor A, Woodrow C. Four-Month Rifapentine Regimens for Tuberculosis. N Engl J Med. 2022 03 17; 386(11):1095.

View in: PubMed
Abanda NN, Djieugou? JY, Khadka VS, Pefura-Yone EW, Mbacham WF, Vernet G, Penlap VM, Deng Y, Eyangoh SI, Taylor DW, Leke RGF. Absence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects 'disputed' rifampicin mutations. Clin Microbiol Infect. 2018 Jul; 24(7):781.e1-781.e3.

View in: PubMed
Abanda NN, Djieugou? JY, Lim E, Pefura-Yone EW, Mbacham WF, Vernet G, Penlap VM, Eyangoh SI, Taylor DW, Leke RGF. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study. BMC Infect Dis. 2017 05 31; 17(1):379.

View in: PubMed
Santos RH, Santos NG, Alves JP, Garcia CA, Rom?o LC, Arguelho ML. Evaluation of the physico-chemical properties of chitosan as a potential carrier for rifampicin, using voltammetric and spectrophotometric techniques. Bioelectrochemistry. 2008 Apr; 72(2):122-6.

View in: PubMed
Arisoy ES, Correa AG, Wagner ML, Kaplan SL. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment. Clin Infect Dis. 1999 Apr; 28(4):778-84.

View in: PubMed
Yajko DM, Madej JJ, Lancaster MV, Sanders CA, Cawthon VL, Gee B, Babst A, Hadley WK. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol. 1995 Sep; 33(9):2324-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals